April 15th, 2019
For the ALS patients in the world,
we hope to deliver Japan-originated ALS treatment

NMPA accepts our filing for Radicut to treat ALS in China
Mitsubishi Tanabe Pharma Corporation (MTPC) (Head Office: Osaka; President &Representative Director, CEO: Masayuki Mitsuka), announced today that theNational Medical Products Administration (NMPA) has accepted MTPC’s filingthrough Mitsubishi Tanabe Pharma Development (Beijing) Co., Ltd. that is MTPC’sR&D subsidiary in China for Radicut (Edaravone, Japan name: RADICUT® BAG forI.V. Infusion 30mg) an intravenous treatment for amyotrophic lateral sclerosis (ALS),a rapidly progressive neurological disease on April 3rd.
MTPC accomplished the clinical research program in patients diagnosed with ALS in Japan.
Edaravone was approved for use as a treatment for ALS in Japan, June 2015, following
U.S., Canada and Swiss.
ALS is an idiopathic neurodegenerative disease in which motor neurons selectivelydegenerate and vanish. Muscle strength declines throughout the entire body,including the limb, facial, and respiratory muscles, and muscular atrophy progress.
While the cause for the majority of cases is not well understood but may involve
genetic and environmental factors. It is one of the most well-known neuromusculardiseases, affecting approximately two in 100,000 people worldwide. As many as
20,000 or 30,000 people are estimated to be affected by ALS in China.
Edaravone is a free-radical scavenger that was discovered by MTPC. It is thoughtthat edaravone has the effect of scavenging free radicals, which increase in ALS,
protecting motor neurons from oxidative stress, and delaying the decline in muscle
strength and the progress of muscular atrophy.
MTPC will strive to deliver edaravone to patients fighting against ALS all over theworld.

Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department
Media contacts: TEL:+81 6 6205 5119
Investor contacts: TEL:+81 6 6205 5110

1/2

<Reference>■ About edaravone
Edaravone is a free-radical scavenger that was discovered by Mitsubishi TanabePharma. It was approved by the Japanese Ministry of Health, Labor and Welfare inApril 2001 as a treatment agent for the acute stage of cerebral infarction. In Japan,
it is being marketed under the product name RADICUT®. Edaravone has the effectof scavenging free radicals that arise accompanying cerebral ischemia, controlling
the lipid peroxidation reaction, and protecting neurons in the region of the ischemia
and the surrounding region. Accordingly, it is thought that edaravone has the effectof scavenging free radicals, which increase in ALS, protecting motor neurons fromoxidative stress, and delaying the decline in muscle strength and the progress ofmuscular atrophy.

■About Mitsubishi Tanabe Pharma Development (Beijing) Co., Ltd.
Mitsubishi Tanabe Pharma Development (Beijing) Co., Ltd. is a wholly-owned
subsidiary founded by MTPC in Beijing, China, in 2006. The company is engaged inself-promoted clinical development aimed at receiving marketing approval ofpharmaceuticals in China. As a key base of the MTPC group in China, it promotes
business in China by developing new drugs and receiving their approval in thecountry, thereby seeking to enhance MTPC's corporate value.

2/2